← Leaderboards
Richard D Olson
Gem Pharmaceuticals, Llc
$2,353,198
Attributed
$2,353,198
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$2,353,198 · 4
By mechanism
P50$1,465,797 · 1
R42$557,528 · 1
R41$329,873 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Cardiotoxin”
- Steven Edward Lipshultz · University Of Rochester$5,287,637
- Aruni Bhatnagar Bhatnagar · University Of Louisville$3,684,070
- Daret K St Clair · University Of Kentucky$2,387,204
- Laurence H Kedes · University Of Southern California$2,283,589
- Jimmy D. Ballard · University Of Oklahoma Hlth Sciences Ctr$1,821,020
- Arleen B. Rifkind · Weill Medical College Of Cornell Univ$1,761,869
Research focus
CardiotoxinLaboratory RabbitDoxorubicinDrug Screening /EvaluationCytotoxicityCell Growth RegulationDrug Adverse EffectHistopathologyTissue /Cell CultureAnthracyclinesElectrocardiographyLaboratory MouseAntineoplasticsColoradoCollectionBreast NeoplasmsCollaborationsDrug InteractionsCodeBloodCell LineData ManagementBioinformaticsComputer Software
Grant awards (5)
ADMINISTRATIVE CORE$1,465,797
P50 · FY2007 · HD · contact PI
Cardiac Interactions of New Adriamycin Analogs and Taxol$195,590
R41 · FY2004 · HL
Novel Doxorubicin Analogs:Cardiac and Cytotoxic Effects$278,764
R42 · FY2003 · HL
Novel Doxorubicin Analogs:Cardiac and Cytotoxic Effects$278,764
R42 · FY2002 · HL
NOVEL DOXORUBICIN ANALOGS: CARDIAC AND CYTOTOXIC EFFECTS$134,283
R41 · FY2000 · HL